Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211 | Zendy

Roy M. Gulick | Zendy; Zhaohui Su | Zendy; Charles Flexner | Zendy; Michael D. Hughes | Zendy; Paul R. Skolnik | Zendy; Timothy Wilkin | Zendy; Robert Gross | Zendy; Amy Krambrink | Zendy; Eoin Coakley | Zendy; Wayne Greaves | Zendy; Andrew Zolopa | Zendy; Richard C. Reichman | Zendy; Catherine Godfrey | Zendy; Martin Hirsch | Zendy; Daniel R. Kuritzkes | Zendy

Open Access

Phase 2 Study of the Safety and Efficacy of Vicriviroc, a CCR5 Inhibitor, in HIV‐1–Infected, Treatment‐Experienced Patients: AIDS Clinical Trials Group 5211

Author(s) -

Roy M. Gulick,

Zhaohui Su,

Charles Flexner,

Michael D. Hughes,

Paul R. Skolnik,

Timothy Wilkin,

Robert Gross,

Amy Krambrink,

Eoin Coakley,

Wayne Greaves,

Andrew Zolopa,

Richard C. Reichman,

Catherine Godfrey,

Martin Hirsch,

Daniel R. Kuritzkes

Publication year - 2007

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/518797

Subject(s) - regimen , tolerability , placebo , medicine , adverse effect , ritonavir , clinical endpoint , randomized controlled trial , viral load , gastroenterology , clinical trial , immunology , human immunodeficiency virus (hiv) , antiretroviral therapy , pathology , alternative medicine

Vicriviroc, an investigational CCR5 inhibitor, demonstrated short-term antiretroviral activity in a phase 1 study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research